EGFR and lung carcinoma: In the first human trial of a TargomiR drug, MesomiR-1, the miRNA mimic was the reported tumor suppressing transcript miR-16 and the targeting moiety was an antibody to the epidermal growth factor receptor (EGFR) that is consistently deregulated in lung cancer cells (Reid et al., 2016; van Zandwijk et al., 2017).